J&J is off to a strong start in 2026

April 14, 2026

TL;DR

J&J reported Q1 revenue of $24.06 billion, surpassing LSEG consensus, with operational revenue up 6.4% excluding foreign exchange.
Adjusted EPS came in at $2.70, beating expectations.
Key growth drivers included blood-cancer therapy Darzalex (sales up 22.5%) and autoimmune treatment Tremfya (sales up 68%).
The company launched Icotyde, the first oral IL-23 inhibitor for psoriasis, with CEO projecting it could become one of J&J's largest products.
MedTech segment revenue was $8.64 billion, slightly exceeding consensus, with the Ottava robotic surgery system noted as a key development.
Stelara's revenue fell nearly 60% due to patent expiration and biosimilar competition.
J&J raised its full-year guidance for operational sales growth and adjusted EPS.
The company reiterated its confidence in achieving double-digit revenue growth by the end of the decade, with a business review meeting scheduled for December 8th.

Continue reading the original article